Hybrigenics is a biopharmaceutical company focusing its internal R & D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics Taxotere , the current gold – standard chemotherapeutic treatment for this indication ‘ development program in Inecalcitol, a vitamin D analogue for the treatment of hormone refractory prostate cancer in combination with Sanofi-Aventis is based. ‘.

Hybrigenics ‘ flagship program is Inecalcitol developed in the therapeutic indication for hormone in combination in combination with the gold standard Taxotere treatment in the Phase II. Tolerance study is progressing rapidly: the oral dose of 300 micrograms per day has been tested over the summer, revealing an excellent tolerance and the treatment of patients with 600 micrograms oral doses has just begun.Five in five adults are experiences chronic pain in their lives. To to effectively reduce pains, primarily cases of chronic pain, use of strong analgesics such as opioids expands. However, a significant amount of patients, that pain do not satisfied with their treatment , showed her opioid therapy out against medical write recommendation The important reasons are gastrointestinal side effects as nausea and vomiting associated in the early days and obstruction the the course of ongoing treatment , GI tolerability is one of the leaders cause to stopping treatment on patients who consume prescription pain relievers..

The primary objectives of study are which the safety and tolerance of iV infusions of CD-NP to patients with failure. Target receptor, include measurements on the blood pressure, heart rate, serum potassium and renal impairment via glomerular filtration rate charged. Clinical evaluation comprise urine flow rate sodium elimination rate or plasma cGMP, a second messenger of target receptor. The trial is expected until on approximately 35 patient. To results of the study is expected to be available in 2008.

.

Other Posts From Category "pharmacy":

Related Posts